Clinical Trial Update: Study to Evaluate Psoriasis Severity and Its Psychosocial Impact Using the Simplified Psoriasis Index (SPI), as Well as Long-term Safety, Tolerability and Efficacy of Secukinumab Administered Subcutaneously in Patients With Moderate to Severe Psoriasis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating secukinumab for moderate to severe psoriasis, focusing on disease severity, psychosocial impact, long-term safety, tolerability, and ef…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• Secukinumab (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2019-04-17